Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939707 | 0.84 | ALOX5 (0.56) | ALOX5NPC1RAB9ACA12CA1 | |
| SCHEMBL1359920 | 0.80 | P2RY14 (0.45) | ALOX5ARMAOBP2RY14MAOA | |
| SCHEMBL1360827 | 0.76 | ALOX5 (0.59) | ALOX5NPC1RAB9AHPGDCA12 | |
| SCHEMBL19612330 | 0.74 | ALOX5 (0.61) | ALOX5NPC1RAB9ACA12CA1 | |
| SCHEMBL2004893 | 0.73 | AR (0.64) | PPARGNPC1RAB9AARHPGD | |
| SCHEMBL31487931 | 0.72 | MAOB (0.63) | ALOX5NPC1RAB9AARHPGD | |
| SCHEMBL27635587 | 0.72 | MAOB (0.63) | ALOX5NPC1RAB9AARHPGD | |
| SCHEMBL19612377 | 0.72 | ALOX5 (0.58) | ALOX5NPC1RAB9AMAOBACHE | |
| SCHEMBL19612473 | 0.71 | ALOX5 (0.61) | ALOX5NPC1RAB9ACA12CA1 | |
| SCHEMBL31487932 | 0.71 | MAOB (0.61) | NPC1RAB9AARHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217032-B2 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | ELI LILLY AND COMPANY (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1709021-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073204-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | GPER1, ESR1, HSD17B11 | ALOX5 351/4885PPARG 784/4885NPC1 1814/4885 |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | GPER1, ESR1, HSD17B11 | ALOX5 351/4885PPARG 784/4885NPC1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.